This Week's Three Risers
Three unrelated stories put the same three tickers on top of Stoxcraft's screener this week. AbCellera (ABCL) is up 85% after a clinical trial win. Hertz (HTZ) is up roughly 49% after an earnings beat triggered a short squeeze.
Nebius (NBIS) is up around 54% on a genuine AI-infrastructure earnings blowout. What actually happened, and what Stoxcraft's own scores say about each name, matters now that the headline has already moved the price.
AbCellera (ABCL): A Hot Flash Drug Turns a Biotech Around
AbCellera shares jumped as much as 41% on August 10 after the company announced positive topline results from a Phase 2 trial of ABCL635, an experimental non-hormonal treatment for moderate-to-severe hot flashes tied to menopause. The study hit its primary efficacy endpoint, an 83% mean reduction in hot flash frequency at week four after a single dose, with a placebo-adjusted difference of 8.8 events per day versus 3.5 for placebo.
The move wasn't a one-day spike. ABCL has now closed higher for six consecutive sessions, a cumulative gain of roughly 85% that pushed the stock to a new 52-week high near $11.50. Cantor Fitzgerald raised its price target to $12, Stifel to $9, and Piper Sandler issued a fresh buy rating.
On Stoxcraft's scorecard, that enthusiasm shows up almost entirely on the technical side. A Performance Score of 6.0 sits comfortably above the Healthcare sector median, but the Health Score of just 1.8 is among the weakest in Stoxcraft's coverage, since the company still burned $146 million in net income over the trailing year and remains years from turning ABCL635 into revenue. The 2-star Overall Rating and an RSI near 84, deep in overbought territory, capture that gap between a hot chart and a still-fragile balance sheet.
Hertz (HTZ): An Earnings Beat Lights the Fuse on a Short Squeeze
A Q2 beat lit the fuse under Hertz on August 6: revenue of $2.396 billion, up 10% year over year and above the $2.28 billion consensus, and an adjusted loss of just $0.11 per share against a $0.24 loss expected. The beat was real, but the size of the move wasn't just about the numbers. Hertz carries roughly 31% short interest, and the report triggered a classic squeeze that carried the stock from around $1.50 to nearly $3 before it stalled and pulled back to today's $2.24, still a gain of about 49% for the week.
Susquehanna cut its price target to $2.50 from $5.50 even while keeping a Neutral rating, and Pershing Square has reportedly exited its stake. Stoxcraft's scores explain the skepticism: Hertz's Performance Score is just 0.5 and its Health Score is 1.0, both near the bottom of the entire coverage universe, while the Risk Score sits at a maxed-out 10.0, meaning this is about as volatile and fundamentally strained as a stock gets on the platform. The 0.5-star Overall Rating is the lowest possible read: a balance sheet carrying roughly $19.2 billion in debt against negative equity, dressed up this week by a squeeze rather than fixed by one.
Nebius (NBIS): The One Riser Backed by an Actual Earnings Blowout
Nebius, the Amsterdam-based AI-cloud infrastructure operator, reported Q2 2026 revenue of $582.3 million, up 454% year over year, and turned adjusted EBITDA positive for the first time. Management raised year-end contracted power guidance to 5 gigawatts, up from roughly 4 gigawatts in May.
The quarter also included a new multi-year compute deal with Reflection AI worth more than $1 billion through 2029, layered on top of existing agreements with Microsoft and Meta. The stock has climbed roughly 54% this week, jumping as much as 34% in a single session on August 12 alone.
Lined up side by side, Stoxcraft's own scorecard makes the gap between these three moves obvious: one standout, one deep value trap, and one priced for years of growth already baked in. Risk Score runs in the opposite direction from the other two: the higher the number, the more volatile and fundamentally strained the stock.
Nebius carries the strongest fundamentals of the three on that scorecard, with a Performance Score of 8.9 among the highest in the Technology sector and a Health Score of 5.3 that's respectable for a company still scaling infrastructure this fast. The 3.5-star Overall Rating and a Hold signal capture the tension here: real revenue growth and real fundamentals, but a Risk Score of 7.7, above the Technology sector median, and a P/E ratio above 700 both flag a valuation priced for years of continued hypergrowth.
Beyond this week's snapshot, all three names stay trackable on Stoxcraft's screener as their scores keep moving. Pull up the full comparison below to see how each stacks up right now:
Outlook: What to Watch Next
AbCellera still needs to design and fund a Phase 3 program for ABCL635, and any delay or a weaker-than-expected readout would hit a stock that has already priced in a blockbuster outcome. Hertz's next real test is whether the operational improvement shows up again in Q3 results, expected in late October or November, since a short squeeze without a follow-through beat tends to fade fast. The stock's failed attempts to clear $3 already suggest that.
Nebius investors should watch for confirmation that this quarter's compute deals translate into contracted revenue on schedule, and whether upcoming 2027 guidance validates the current growth-priced valuation.
None of the three companies has a scheduled catalyst in the next two weeks beyond routine trading, so barring new news, this week's moves are likely to consolidate until the next earnings date, trial update, or contract disclosure lands.
